ea0098c8 | Clinical – Chemo/SSA/Biologics | NANETS2023
Luo MS Rosa
, Casagrande MD, PhD Alessandra
, Oun BA Sonic
, Wang MSPH Yang
, Scott Struthers PhD R.
, Usiskin MD Keith
, Krasner MD Alan
Background: Paltusotine is an investigational oral, once-daily, small molecule somatostatin receptor type 2 agonist in development for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors.Methods: This multicenter, open-label, phase 1 study enrolled participants with mild, moderate, and severe hepatic impairment based on Child-Pugh classification and matched healthy participants. A single 20-mg oral dose of paltusotine...